PIK3CB and neoplasm: As mentioned previously, unlike PTEN-null BC, in PIK3CA-mutant BC the p110α isoform predominantly drives PI3K signalling instead of p110β, leading to investigation of PI3Kα inhibitors such as BYL719 as potential therapeutics for these tumours.